MedTrace Logo

A Phase 1, First Time in Humans Study of NST-1024

NCT04630366 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2022-12-02

No results posted yet for this study

Summary

A first time in man study of NST-1024

Conditions

  • Hypertriglyceridemia

Interventions

DRUG

NST-1024

NST-1024

DRUG

Placebo

Matching placebo to NST-1024

Sponsors & Collaborators

  • NorthSea Therapeutics B.V.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-10-27
Primary Completion
2022-06-20
Completion
2022-06-20

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04630366 on ClinicalTrials.gov